Skip to main content
Fig. 5 | Journal of Experimental & Clinical Cancer Research

Fig. 5

From: Elevated transcription and glycosylation of B3GNT5 promotes breast cancer aggressiveness

Fig. 5

Knockout of B3GNT5 suppressed tumorigenicity in vitro and in vivo, and elevated B3GNT5 expression predicts poor clinical outcomes. A, B Soft-agar assay was performed using MDA-MB231 and BT549 cells with or without B3GNT5 knockout (A) as well as MCF7 cells with stable empty vector or B3GNT5-WT-Flag cDNA (B). Data are presented as the percentage of wild-type or vector cell lines. Data are shown as mean ± SD based on three independent experiments. C, D MDA-MB231 (C) and SUM159 cells (D) with or without B3GNT5 knockout were injected into the mammary fat pad of nude mice. Tumor growth was measured every two days. On day 21, mice were sacrificed and tumor weights were recorded. Data are presented as mean ± SEM of six mice. *p < 0.05 by Student’s t test. E MDA-MB231 cells with or without B3GNT5 knockout were transplanted into the mammary fat pad of nude mice. 12 weeks after transplantation, tumor formation was analyzed by extreme limiting dilution analysis. F Box-plots indicated B3GNT5 expression in different tumor sizes of breast cancer from NKI295 dataset. Comparisons are made using the two-tailed Student’s t-test. G Box-plots indicated B3GNT5 expression in different histological grades of breast cancer from GSE21653 and GSE1456 datasets. Comparisons between two groups are made using the two-tailed Student’s t-test. H Kaplan-Meier survival analysis for OS and DMFS of patients in GSE20685 dataset according to B3GNT5 expression status. The p-value is determined using the log-rank test

Back to article page